News & Media
SK Life Science
Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company
General business
Strategic alliance and partnership opportunities
Media inquiries and PR
Grant and investigator initiated proposals
Sponsorship requests
Medical information inquiries or report adverse events
Phone: 1-866-OKSKLSI (657-5574)
Email: medicalinfo@sklsi.com
SK Life Science at a glance
-
Headquarters location
PARAMUS, NJ
-
R&D Begins
1993
-
Parent Company
SK Life Science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group
-
Number of employees
200+ EMPLOYEES
-
Disease Category Focus
CNS
-
Pipeline
8 compounds under clinical development
Newsroom
4/15/2021
SK life science Reports Effectiveness Of Long-Term Use With Cenobamate
Full release4/08/2021
SK life science To Present Latest Cenobamate Data at the American Academy of Neurology 2021 Virtual Annual Meeting
Full release3/30/2021
ONTOZRY® (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults
Full release1/29/2021
Cenobamate Receives Positive CHMP Opinion for Adjunctive Treatment of Focal-Onset (Partial-Onset) Seizures
Full release1/04/2021
SK Biopharmaceuticals To Sell Arvelle Therapeutics Stake As Part Of Angelini Pharma’s Acquisition Of Arvelle Therapeutics
Full release12/01/2020
SK life science Presents Latest Cenobamate Data at the American Epilepsy Society AES2020 Virtual Event
Full release10/29/2020
SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open Innovation
Full release10/13/2020
SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan
Full release9/11/2020
SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia
Full release7/15/2020
SK life science Expands Support for the Epilepsy Foundation to Advance Epilepsy Awareness, Research, Education and Care
Full release